Oppenheimer Asset Management Inc. Purchases Shares of 81,327 Avantor, Inc. $AVTR

Oppenheimer Asset Management Inc. purchased a new position in shares of Avantor, Inc. (NYSE:AVTR) in the 2nd quarter, HoldingsChannel.com reports. The institutional investor purchased 81,327 shares of the company’s stock, valued at approximately $805,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Private Trust Co. NA raised its holdings in shares of Avantor by 46.2% during the 4th quarter. Private Trust Co. NA now owns 2,769 shares of the company’s stock valued at $32,000 after buying an additional 875 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Avantor by 28.1% in the 3rd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,123 shares of the company’s stock worth $49,000 after buying an additional 905 shares during the last quarter. Osaic Holdings Inc. boosted its stake in Avantor by 60.9% in the second quarter. Osaic Holdings Inc. now owns 2,810 shares of the company’s stock worth $38,000 after buying an additional 1,064 shares in the last quarter. UMB Bank n.a. grew its position in Avantor by 17.6% during the fourth quarter. UMB Bank n.a. now owns 7,371 shares of the company’s stock valued at $84,000 after acquiring an additional 1,101 shares during the last quarter. Finally, EverSource Wealth Advisors LLC grew its position in Avantor by 119.1% during the second quarter. EverSource Wealth Advisors LLC now owns 2,187 shares of the company’s stock valued at $29,000 after acquiring an additional 1,189 shares during the last quarter. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

Avantor Stock Down 1.0%

Shares of Avantor stock opened at $13.52 on Tuesday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.18 and a current ratio of 1.78. Avantor, Inc. has a 52-week low of $7.26 and a 52-week high of $15.93. The stock has a market capitalization of $9.14 billion, a price-to-earnings ratio of -16.10, a P/E/G ratio of 10.29 and a beta of 0.89. The company’s 50 day moving average price is $11.28 and its 200-day moving average price is $9.55.

Avantor (NYSE:AVTR) last posted its quarterly earnings results on Wednesday, July 29th. The company reported $0.21 EPS for the quarter, beating analysts’ consensus estimates of $0.19 by $0.02. The company had revenue of $1.69 billion during the quarter, compared to analyst estimates of $1.61 billion. Avantor had a negative net margin of 8.81% and a positive return on equity of 9.92%. The firm’s revenue was up .5% compared to the same quarter last year. During the same period in the prior year, the business posted $0.24 EPS. Avantor has set its FY 2026 guidance at 0.800-0.830 EPS. Equities research analysts forecast that Avantor, Inc. will post 0.81 EPS for the current year.

Analyst Ratings Changes

AVTR has been the subject of a number of recent research reports. Wall Street Zen upgraded shares of Avantor from a “hold” rating to a “buy” rating in a report on Saturday, June 27th. Wells Fargo & Company increased their target price on shares of Avantor from $14.00 to $16.00 and gave the company an “overweight” rating in a report on Thursday, July 30th. Wolfe Research upgraded shares of Avantor from a “strong sell” rating to a “hold” rating in a research report on Thursday, July 30th. Royal Bank Of Canada boosted their price target on shares of Avantor from $9.00 to $14.00 and gave the stock a “sector perform” rating in a research note on Thursday, July 30th. Finally, Evercore set a $10.50 price objective on Avantor in a research note on Monday, July 6th. Two investment analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Avantor presently has an average rating of “Hold” and a consensus target price of $12.00.

About Avantor

Avantor, Inc (NYSE:AVTR) is a global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company delivers essential solutions that support research, development, production and safety applications. Its product portfolio spans from high-purity chemicals and reagents to biologics and cell culture media, as well as lab equipment, consumables and custom manufacturing services.

Avantor’s offerings are organized across two primary segments.